It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Metastasis arises from disseminated tumour cells (DTCs) that are characterized by intrinsic phenotypic plasticity and the capability of seeding to secondary organs. DTCs can remain latent for years before giving rise to symptomatic overt metastasis. In this context, DTCs fluctuate between a quiescent and proliferative state in response to systemic and microenvironmental signals including immune-mediated surveillance. Despite its relevance, how intrinsic mechanisms sustain DTCs plasticity has not been addressed. By interrogating the epigenetic state of metastatic cells, we find that tumour progression is coupled with the activation of oncogenic enhancers that are organized in variable interconnected chromatin domains. This spatial chromatin context leads to the activation of a robust transcriptional response upon repeated exposure to retinoic acid (RA). We show that this adaptive mechanism sustains the quiescence of DTCs through the activation of the master regulator SOX9. Finally, we determine that RA-stimulated transcriptional memory increases the fitness of metastatic cells by supporting the escape of quiescent DTCs from NK-mediated immune surveillance. Overall, these findings highlight the contribution of oncogenic enhancers in establishing transcriptional memories as an adaptive mechanism to reinforce cancer dormancy and immune escape, thus amenable for therapeutic intervention.
Metastasis arises from disseminated tumour cells (DTCs) while the underlying mechanism of DTCs plasticity remains underexplored. Here, the authors show that spatially organized oncogenic enhancers on chromatin sustain the establishment of retinoic acid (RA)-stimulated transcriptional memory through activation of SOX9, supporting the escape of quiescent DTCs from NK-mediated immune surveillance.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details












1 Computational and Integrative Biology (CIBIO), University of Trento, Department of Cellular, Trento, Italy (GRID:grid.11696.39) (ISNI:0000 0004 1937 0351)
2 Computational and Integrative Biology (CIBIO), University of Trento, Department of Cellular, Trento, Italy (GRID:grid.11696.39) (ISNI:0000 0004 1937 0351); Faculty of Medicine Nursing and Medical Sciences, The University of Adelaide, The South Australian Immunogenomics Cancer Institute, Adelaide, Australia (GRID:grid.1010.0) (ISNI:0000 0004 1936 7304)
3 Computational and Integrative Biology (CIBIO), University of Trento, Department of Cellular, Trento, Italy (GRID:grid.11696.39) (ISNI:0000 0004 1937 0351); Istituto Italiano di Tecnologia IIT, Milan, Italy (GRID:grid.25786.3e) (ISNI:0000 0004 1764 2907)
4 Computational and Integrative Biology (CIBIO), University of Trento, Department of Cellular, Trento, Italy (GRID:grid.11696.39) (ISNI:0000 0004 1937 0351); Department of Epigenetics Van Andel Institute, Grand Rapids, USA (GRID:grid.251017.0) (ISNI:0000 0004 0406 2057)
5 Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Department of Health Promotion, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517)
6 Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Department of Surgical, Palermo, Italy (GRID:grid.10776.37) (ISNI:0000 0004 1762 5517)
7 University of Modena and Reggio Emilia, Department of Life Sciences, Modena, Italy (GRID:grid.7548.e) (ISNI:0000 0001 2169 7570)
8 University of Cologne, Center for Molecular Medicine Cologne (CMMC), Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
9 CSIC/Universidad de Cantabria, Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC), Santander, Spain (GRID:grid.7821.c) (ISNI:0000 0004 1770 272X)
10 Icahn School of Medicine at Mount Sinai, Department of Pharmacological Sciences, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
11 Medical Center-University of Freiburg, Department of Urology, Freiburg, Germany (GRID:grid.5963.9) (ISNI:0000 0004 0491 7203); German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK) partner site Freiburg, Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)